Tim Smith

In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.

In this discussion with Dr. Hunter, the findings his team presented at ACR 2023 were explored, including a discussion about their implications for the future of osteoarthritis treatment.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.

This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.

This research into obinutuzumab may provide some hope for those facing the most common cause of kidney damage among patients with lupus.

In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

This new research presented at ACR Convergence 2023 led to several notable findings for patients with rheumatoid arthritis.

This new data may help health policymakers to better strategize their approaches to management of childrens’ nutritional anemias.

This new data showed that spreading awareness about pneumococcal infection and prophylaxis could help to improve health outcomes and reduce mortality related to infections in those with SCD.

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.

This new research looked at a nationwide birth cohort of mother–child pairs in Japan, allowing for a wide array of data on this less well-studied topic.

This is the first research to allow for greater insight into the impacts on providers of a nationwide change to an adalimumab biosimilar.

This study provides further support for the efficacy of this biosimilar, allowing for potential future reduction in costs for patients with IBD.

This new research opens the door for further biological agent use in IBD therapy, helping to expand patients’ array of options when seeking IBD treatment in different countries.

Despite the lack of association with all-cause mortality, this research emphasizes the value of focusing on patients’ psychological well-being due to increased suicide risk among fibromyalgia patients.

This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.